104 related articles for article (PubMed ID: 16327815)
1. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Morabito F; Stelitano C; Luminari S; Mammi C; Marcheselli L; Callea V; Gentile M; Polimeno G; Merli F; Molica S; Gobbi P; Angrilli F; Brugiatelli M; Federico M
Bone Marrow Transplant; 2006 Feb; 37(3):283-8. PubMed ID: 16327815
[TBL] [Abstract][Full Text] [Related]
2. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy and autologous stem cell transplantation for Hodgkin's lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience.
Akhtar S; Abdelsalam M; El Weshi A; Al Husseini H; Janabi I; Rahal M; Maghfoor I
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S37-S40. PubMed ID: 18724297
[TBL] [Abstract][Full Text] [Related]
4. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.
Morschhauser F; Brice P; Fermé C; Diviné M; Salles G; Bouabdallah R; Sebban C; Voillat L; Casasnovas O; Stamatoullas A; Bouabdallah K; André M; Jais JP; Cazals-Hatem D; Gisselbrecht C;
J Clin Oncol; 2008 Dec; 26(36):5980-7. PubMed ID: 19018090
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
Ballova V; Ladicka M; Vranovsky A; Lakota J
Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
[TBL] [Abstract][Full Text] [Related]
7. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ
Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
10. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL).
Longo G; Fiorani C; Sacchi S; Callea V; Lombardo M; Federico M; Stelitano C; Angrilli F; Vallisa D; Gobbi PG; Ilariucci F; Frassoldati A; Petrini M; Silingardi V
Haematologica; 1999 May; 84(5):425-30. PubMed ID: 10329921
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.
Czyz J; Hellmann A; Dziadziuszko R; Hansz J; Goździk J; Hołowiecki J; Stella-Hołowiecka B; Kachel Ł; Knopińska-Posłuszny W; Nagler A; Meder J; Walewski J; Lampka E; Sułek K; Sawicki W; Lange A; Forgacz K; Suchnicki K; Pacuszko T; Skotnicki A; Mensah P; Jurczak W; Kuliczkowski K; Wróbel T; Mazur G; Dmoszyńska A; Wach M; Robak T; Warzocha K
Bone Marrow Transplant; 2002 Jul; 30(1):29-34. PubMed ID: 12105774
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
[TBL] [Abstract][Full Text] [Related]
15. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation.
Thomson KJ; Peggs KS; Smith P; Cavet J; Hunter A; Parker A; Pettengell R; Milligan D; Morris EC; Goldstone AH; Linch DC; Mackinnon S
Bone Marrow Transplant; 2008 May; 41(9):765-70. PubMed ID: 18195684
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
17. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
18. Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy.
Czyz J; Szydlo R; Knopinska-Posluszny W; Hellmann A; Gozdzik J; Hansz J; Smolewski P; Robak T; Osowiecki M; Walewski J; Avigdor A; Nagler A; Zemelka T; Pawlicki M; Sawicki Z; Wojtukiewicz M; Kachel L; Holowiecki J; Charlinski G; Jedrzejczak WW
Bone Marrow Transplant; 2004 Jun; 33(12):1225-9. PubMed ID: 15094747
[TBL] [Abstract][Full Text] [Related]
19. Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology.
Won SC; Han JW; Kwon SY; Shin HY; Ahn HS; Hwang TJ; Yang WI; Lyu CJ
Ann Hematol; 2006 Nov; 85(11):787-94. PubMed ID: 16932891
[TBL] [Abstract][Full Text] [Related]
20. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study.
Oehler-Jänne C; Taverna C; Stanek N; Negretti L; Lütolf UM; Ciernik IF
Hematol Oncol; 2008 Jun; 26(2):82-90. PubMed ID: 18085574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]